Key points
- Merger with Chemist Warehouse completed in February 2025
- First full-year results post-merger showing significant growth
- Strong financial performance with revenue up 80.5% and NPAT up 34.9%
- Dividend of 2.0 cents per share declared
- Strategic focus on domestic and international growth
Full summary
Sigma Healthcare Ltd's 2026 Annual Report details the company's first full-year results since the merger with Chemist Warehouse in February 2025. The report highlights significant growth with sales revenue from ordinary activities reaching $10,834,966 and net profit after tax (NPAT) at $708,652. The merger has enabled Sigma to leverage Chemist Warehouse's retail expertise and Sigma's wholesale capabilities, resulting in a diversified and scaled healthcare business. The company also announced a fully franked final dividend of 2.0 cents per share, payable in September 2026. The report emphasizes the strategic progress made in integrating the two businesses and the early delivery of synergy benefits, with a targeted $100 million per annum in synergies by FY29. The outlook remains positive with a focus on domestic growth and measured international expansion.
Guidance
Revenue: $10.8 billion, NPAT: $708.7 million, Dividend: 2.0 cents per share
Outlook
Sigma Healthcare Ltd is focused on leveraging its enhanced scale and diversified platform to deliver sustained earnings and long-term shareholder value. The company plans to continue disciplined capital management, cash generation, and shareholder returns.